SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes

Inclusion Criteria: * Diagnosis of recurrent or metastatic SCCHN or any site except lip, thyroid, salivary gland, or nasopharynx. * No known FDA-approved therapy available that's expected to prolong survival by greater than 3 months. * Tumors with at least one of the following known mutations in the PI-3K signaling pathway, via assays performed in a CLIA-approved setting (Foundation Medicine FoundationOne test will be used. This assay uses a cut-off of 5% allele fraction for mutations. Allele fraction will be requested on each sample): 1. PIK3CA, 2. PIK3CG, 3. PIK3R1, PIK3R5 and PIK3AP1 (regulatory subunits), 4. AKT and mTOR, or 5. PTEN Note: PIK3CA amplification is not eligible. * Prior receipt of platinum-containing chemotherapy for recurrent/metastatic disease or a history of progression of disease within 6 months of receiving platinum as part of concurrent chemoradiation. * Disease must not be amenable to potentially curative treatment.. * Has recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy. * Myelosuppressive chemotherapy: At least 3 weeks since completion (6 weeks for nitrosourea) * Biologic (anti-neoplastic agent): At least 14 days since completion of therapy with a biologic agent. * Radiation (XRT):1 week must have elapsed from prior palliative XRT to non-target lesions. * Adequate Bone Marrow Function Defined for all subjects (including status post SCT): * Peripheral absolute neutrophil count (ANC) 1000/mm3; Note: must be \>7 days from use of hematopoietic growth factor or 21 days from pegfilgastrim * Platelet count 75,000/ mm3 (transfusion independent for \>7 days) * Hemoglobin 8.0 g/dL (may receive transfusions) * Adequate Renal Function Defined As: * Serum creatinine ≤ 1.5 x institution's ULN (upper limit of normal), or * Creatinine clearance 50 ml/min * Adequate Liver and Pancreatic Function Defined As: * Total bilirubin 1.5 x upper limit of normal, and * ALT or AST 5 x upper limit of normal, and * Albumin 2 g/dL * Adequate Central Nervous System Function Defined As: * Subjects with seizure disorder may be enrolled if on anticonvulsants and seizures are well controlled. Exclusion Criteria: * Brain metastases or spinal cord compression, unless treatment was completed at least 4 weeks before study entry, and stable without steroid treatment for at least 4 weeks. * Evidence of severe or uncontrolled systemic diseases (e.g., unstable or uncompensated respiratory, cardiac \[including life threatening arrhythmias\], hepatic, or renal disease). * Unresolved toxicity ≥ CTCAE Grade 2 from previous anti-cancer therapy except alopecia or long-term radiation toxicity (radiation related toxicity 3 months or greater after radiation exposure). * Presence of cardiac impairment defined as: * Prior history of cardiovascular disease including heart failure that meets New York Hearth Association (NYHA) class III and IV definitions; OR * History of myocardial infarction/active ischemic heart disease within one year of study entry; OR * Uncontrolled dysrhythmias; OR * Poorly controlled angina. * Participation in a trial of an investigational agent within the prior 30 days. * Pregnant or breast-feeding females. * History of other malignancies except curatively excised carcinoma in situ of the cervix, non-melanomatous skin carcinoma or superficial bladder cancer or other solid tumors curatively treated with no evidence of disease for 3 years. Other cases will be reviewed and possibly allowed if discussed with and approved by the Principal Investigator. * Patients receiving therapeutic doses of warfarin. * Blood pressure greater than 170/90 or two standard deviations from normal based on age and weight nomogram on three separate measurements.